Form 4: Surrozen CFO Charles O. Williams Acquires 27,000 Options

Charles O. Williams, CFO and COO of Surrozen, Inc., acquired 27,000 options to purchase common stock on May 1, 2024.

Summary

• On May 1, 2024, Charles O. Williams, the CFO and COO of Surrozen, Inc., acquired 27,000 options to buy common stock.
• The exercise price of these options is $9.89.
• The options vest in 48 equal monthly installments starting June 1, 2024, contingent upon continuous service.
• The expiration date for these options is May 1, 2034.
• Following this transaction, Williams directly owns 27,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of an option grant, which is neither overwhelmingly positive nor negative on its own. The grant suggests confidence in the company, but it's a standard practice.

Positives

• The acquisition of options by a key executive like the CFO/COO can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard Form 4 filing related to executive compensation. Option grants are a common way to incentivize and retain key personnel in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Option grants are a typical component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule of 48 months is also fairly standard, aligning executive incentives with long-term company performance.

Stakeholder Impact

• Shareholders may view the option grant as a way to align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates